These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 19843661)

  • 1. Macrophage inhibitory cytokine 1: a new prognostic marker in prostate cancer.
    Brown DA; Lindmark F; Stattin P; Bälter K; Adami HO; Zheng SL; Xu J; Isaacs WB; Grönberg H; Breit SN; Wiklund FE
    Clin Cancer Res; 2009 Nov; 15(21):6658-64. PubMed ID: 19843661
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Macrophage inhibitory cytokine 1 biomarker serum immunoassay in combination with PSA is a more specific diagnostic tool for detection of prostate cancer.
    Li J; Veltri RW; Yuan Z; Christudass CS; Mandecki W
    PLoS One; 2015; 10(4):e0122249. PubMed ID: 25853582
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Measurement of serum levels of macrophage inhibitory cytokine 1 combined with prostate-specific antigen improves prostate cancer diagnosis.
    Brown DA; Stephan C; Ward RL; Law M; Hunter M; Bauskin AR; Amin J; Jung K; Diamandis EP; Hampton GM; Russell PJ; Giles GG; Breit SN
    Clin Cancer Res; 2006 Jan; 12(1):89-96. PubMed ID: 16397029
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum macrophage inhibitory cytokine-1 concentrations correlate with the presence of prostate cancer bone metastases.
    Selander KS; Brown DA; Sequeiros GB; Hunter M; Desmond R; Parpala T; Risteli J; Breit SN; Jukkola-Vuorinen A
    Cancer Epidemiol Biomarkers Prev; 2007 Mar; 16(3):532-7. PubMed ID: 17372249
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Macrophage Inhibitory Cytokine-1 as a Novel Diagnostic and Prognostic Biomarker in Stage I and II Nonsmall Cell Lung Cancer.
    Liu YN; Wang XB; Wang T; Zhang C; Zhang KP; Zhi XY; Zhang W; Sun KL
    Chin Med J (Engl); 2016 Sep; 129(17):2026-32. PubMed ID: 27569226
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Macrophage inhibitory cytokine-1/growth differentiation factor-15 in premalignant and neoplastic tumours in a high-risk pancreatic cancer cohort.
    O'Neill RS; Emmanuel S; Williams D; Stoita A
    World J Gastroenterol; 2020 Apr; 26(14):1660-1673. PubMed ID: 32327914
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Macrophage Inhibitory Cytokine-1 (MIC-1) as A Biomarker for Diagnosis 
and Prognosis of Stage I-II Non-small Cell Lung Cancer].
    Liu Y; Wang X; Wang T; Zhang C; Zhang K; Zang R; Zhi X; Zhang W; Sun K
    Zhongguo Fei Ai Za Zhi; 2016 Apr; 19(4):207-15. PubMed ID: 27118648
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low testosterone at first prostate-specific antigen failure and assessment of risk of death in men with unfavorable-risk prostate cancer treated on prospective clinical trials.
    Atkins KM; Chen MH; Wu J; Renshaw AA; Loffredo M; Kantoff PW; Small EJ; D'Amico AV
    Cancer; 2018 Apr; 124(7):1383-1390. PubMed ID: 29266181
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relevance of MIC-1 in the Era of PSA as a Serum Based Predictor of Prostate Cancer: A Critical Evaluation.
    Bansal N; Kumar D; Gupta A; Chandra D; Sankhwar SN; Mandhani A
    Sci Rep; 2017 Dec; 7(1):16824. PubMed ID: 29203798
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association Between Plasma Levels of Macrophage Inhibitory Cytokine-1 Before Diagnosis of Colorectal Cancer and Mortality.
    Mehta RS; Chong DQ; Song M; Meyerhardt JA; Ng K; Nishihara R; Qian Z; Morikawa T; Wu K; Giovannucci EL; Fuchs CS; Ogino S; Chan AT
    Gastroenterology; 2015 Sep; 149(3):614-22. PubMed ID: 26026393
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of serum creatinine to predict pathologic stage and recurrence among radical prostatectomy patients.
    Merseburger AS; Connelly RR; Sun L; Richter E; Moul JW
    Urology; 2001 Nov; 58(5):729-34. PubMed ID: 11711350
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prespecified 4-Kallikrein Marker Model at Age 50 or 60 for Early Detection of Lethal Prostate Cancer in a Large Population Based Cohort of Asymptomatic Men Followed for 20 Years.
    Vertosick EA; Häggström C; Sjoberg DD; Hallmans G; Johansson R; Vickers AJ; Stattin P; Lilja H
    J Urol; 2020 Aug; 204(2):281-288. PubMed ID: 32125228
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum prostate-specific antigen after radiation therapy for clinically localized prostate cancer: prognostic implications.
    Kavadi VS; Zagars GK; Pollack A
    Int J Radiat Oncol Biol Phys; 1994 Sep; 30(2):279-87. PubMed ID: 7523340
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Macrophage inhibitory cytokine-1 (MIC-1/GDF15): a new marker of all-cause mortality.
    Wiklund FE; Bennet AM; Magnusson PK; Eriksson UK; Lindmark F; Wu L; Yaghoutyfam N; Marquis CP; Stattin P; Pedersen NL; Adami HO; Grönberg H; Breit SN; Brown DA
    Aging Cell; 2010 Dec; 9(6):1057-64. PubMed ID: 20854422
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prostate-specific antigen for pretreatment prediction and posttreatment evaluation of outcome after definitive irradiation for prostate cancer.
    Kuban DA; el-Mahdi AM; Schellhammer PF
    Int J Radiat Oncol Biol Phys; 1995 May; 32(2):307-16. PubMed ID: 7538499
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pretreatment prostate-specific antigen velocity is associated with development of distant metastases and prostate cancer mortality in men treated with radiotherapy and androgen-deprivation therapy.
    Palma D; Tyldesley S; Pickles T;
    Cancer; 2008 May; 112(9):1941-8. PubMed ID: 18338814
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of candidate biomarkers of therapeutic response to docetaxel by proteomic profiling.
    Zhao L; Lee BY; Brown DA; Molloy MP; Marx GM; Pavlakis N; Boyer MJ; Stockler MR; Kaplan W; Breit SN; Sutherland RL; Henshall SM; Horvath LG
    Cancer Res; 2009 Oct; 69(19):7696-703. PubMed ID: 19773444
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prostate cancer and radiation therapy--the message conveyed by serum prostate-specific antigen.
    Zagars GK; Pollack A; von Eschenbach AC
    Int J Radiat Oncol Biol Phys; 1995 Aug; 33(1):23-35. PubMed ID: 7543892
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Circulating MIC-1/GDF15 is a complementary screening biomarker with CEA and correlates with liver metastasis and poor survival in colorectal cancer.
    Wang X; Yang Z; Tian H; Li Y; Li M; Zhao W; Zhang C; Wang T; Liu J; Zhang A; Shen D; Zheng C; Qi J; Zhao D; Shi J; Jin L; Rao J; Zhang W
    Oncotarget; 2017 Apr; 8(15):24892-24901. PubMed ID: 28206963
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aberrant neuropeptide Y and macrophage inhibitory cytokine-1 expression are early events in prostate cancer development and are associated with poor prognosis.
    Rasiah KK; Kench JG; Gardiner-Garden M; Biankin AV; Golovsky D; Brenner PC; Kooner R; O'neill GF; Turner JJ; Delprado W; Lee CS; Brown DA; Breit SN; Grygiel JJ; Horvath LG; Stricker PD; Sutherland RL; Henshall SM
    Cancer Epidemiol Biomarkers Prev; 2006 Apr; 15(4):711-6. PubMed ID: 16614113
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.